[
  {
    "ts": null,
    "headline": "AbbVie Appears Ready To Move Higher",
    "summary": "AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a promising investment despite key risks.",
    "url": "https://finnhub.io/api/news?id=295d3ec5f7d977806ce68604d530aa5a418a88418613a12af81b302748ad63ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739919353,
      "headline": "AbbVie Appears Ready To Move Higher",
      "id": 132781475,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a promising investment despite key risks.",
      "url": "https://finnhub.io/api/news?id=295d3ec5f7d977806ce68604d530aa5a418a88418613a12af81b302748ad63ca"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=ae331011d0051f0f2daf42ced31bc759d35bb30d88348617cc4369ccb4d092a2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739896320,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 132785520,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=ae331011d0051f0f2daf42ced31bc759d35bb30d88348617cc4369ccb4d092a2"
    }
  },
  {
    "ts": null,
    "headline": "Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon",
    "summary": "Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion in cash. Read more here.",
    "url": "https://finnhub.io/api/news?id=c1d6b14105926a08ff7e19ff286d926c37916f912b70debf4d6b1fa4ee9261f2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739845553,
      "headline": "Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon",
      "id": 132765944,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/170096596/image_170096596.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion in cash. Read more here.",
      "url": "https://finnhub.io/api/news?id=c1d6b14105926a08ff7e19ff286d926c37916f912b70debf4d6b1fa4ee9261f2"
    }
  },
  {
    "ts": null,
    "headline": "GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'",
    "summary": "GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's rating from Buy to Strong Buy.",
    "url": "https://finnhub.io/api/news?id=79f9d082cf625de8b867702d2868dea83fc96c4cb55e6dce4daad22a8c0a5645",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739845293,
      "headline": "GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'",
      "id": 132765945,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164210757/image_164210757.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's rating from Buy to Strong Buy.",
      "url": "https://finnhub.io/api/news?id=79f9d082cf625de8b867702d2868dea83fc96c4cb55e6dce4daad22a8c0a5645"
    }
  }
]